Background and study aim: Hepatitis C virus infection represents a potential public health problem worldwide. Many studies have shown markedly higher prevalence of insulin resistance (IR) and type 2 diabetes mellitus (T2DM) among patients with hepatitis C virus (HCV) infection compared to healthy subjects. Fetuin-A is one of the principal hepatokines regulating the human metabolism. This study aimed to estimate the level of Fetuin-A in HCV patients with concomitant T2DM, and its relation to insulin resistance.
Patients and Methods:
The study was conducted on 115 subjects, 87 patients had chronic HCV infection with and without T2DM, diabetic patients without HCV infection and 28 healthy control, they were subjected to full history taking thorough clinical examination, abdominal ultrasonography, routine laboratory investigation including fasting and post prandial blood glucose level and assessment of HOMA-IR, viral markers and serum Fetuin-A level by ELISA.
Results: There was high statistically significant increase of serum Fetuin-A level among HCV with DM patient group followed by HCV group when compared to DM and control groups. Serum Fetuin-A level was higher in HCV patients than non HCV subjects with statistically significant difference.Also,it was higher among diabetic patients than non diabetic subjects with statistically significant difference.Serum Fetuin-A level was positively correlated with glucose homeostasis parameters in both HCV and HCV&D.M patients with high statistically significant difference. At Cut-off value of serum Fetuin-A >5.2 mg/mL, Sensitivity was 54.84, Specificity was 96.30, positive PV 94.4 and negative PV was 65.0 for prediction of IR in HCV patients. While, at Cut-off value of serum Fetuin-A >4.9 mg/mL, sensitivity was 72. 41 , specificity was 79.31, positive PV was 77.8 and negative PV was 74.2 for prediction of DM in HCV patients.
INTRODUCTION
Infection of hepatitis C virus (HCV) is the main cause of viral hepatitis that may cause chronic hepatitis in about 60-80% of patients and also can progress to liver fibrosis, liver cirrhosis and hepatocellular carcinoma at the end [1] . Also, hepatitis C virus infection has many extrahepatic manifestations [2] . Chronic (20) .Also, Fetuin-A can inhibit the activity of insulin receptor tyrosine kinase by blocking the autophosphorylation of insulin receptor substrate-1 and tyrosine kinase, and induce a low grade inflammation that will result in insulin resistance [17] and its comorbidities as metabolic syndrome and also type 2 diabetes [21]. So, this work aimed to estimate the level of Fetuin-A in HCV patients with concomitant T2DM, and its relation to insulin resistance.
PATIENTS AND METHODS
This case-control study included 115 subjects aged (39- Informed consents were obtained from all patients; this study was approved by Ethical committee of faculty of medicine, Zagazig University, in the period from April 2016 to May 2017. The studied individuals were age and sex matched, randomly selected and divided into 4 groups :  Group I: Chronic HCV patients without diabetes (29 subjects).  Group II: Chronic HCV patients with diabetes (29 subjects).  Group III: Diabetic patients (T2DM) without HCV (29 subjects).  Group IV: Healthy controls (28 subjects).
Exclusion Criteria :
 Cirrhotic patients. 
Statistical Analysis :
The collected data were computerized and statistically analyzed using SPSS 
RESULTS
There is statistically significant difference as regard BMI among studied groups with higher value reported in HCV & DM and DM patients (Table 1 ). There was statistically significant difference of ALT, AST levels among studied groups which were higher in HCV & DM followed by HCV when compared to DM and control groups (Data not shown). There was statistically significant difference as regard lipid profile among different groups, where LDL, TG, TC levels were elevated significantly and HDL level was decreased in HCV&DM followed by DM when compared to HCV and control groups (Data not shown).
There is high statistically significant increase of glucose homeostasis parameters among HCV & DM patients group when compared to other groups ( Table 2) .
As regard FBS, 2-hour postprandial blood glucose and HbA1C there are high statistically significant differences among different group except HCV vs. control. According to insulin level, there is statistically significant difference among different groups. Moreover, HOMA-IR reveals statistically significant difference among all groups except HCV&DM vs. DM (Table 3) .
There is high statistically significant increase of serum Fetuin-A level among HCV & DM followed by HCV patient groups when compared to DM and control groups (Table 4 ).
Serum Fetuin-A level is higher in HCV patients than non HCV subjects with statistically significant difference. Also, it is higher among diabetic patients than non diabetic subjects with statistically significant difference ( Table 6 ).
There was a highly significant positive correlation between Fetuin-A and BMI among all studied subjects (Data not shown). Also, there was positive correlation between serum Fetuin-A and TG, LDL and negative correlation with HDL level with significant difference in the whole studied subjects (Data not shown).
Serum Fetuin-A level is positively correlated with glucose homeostasis parameters in both HCV and HCV&D.M patients with high statistically significant difference. Moreover, serum Fetuin-A level is inversely correlated with age in HCV patients with statistically significant difference. Also, negative correlations between serum Fetuin-A and liver enzymes were reported among each group but without statistically significant difference (Table 7) .
At Cut-off value of serum Fetuin-A >5.2 mg/mL, Sensitivity 54.84, Specificity 96.30, positive PV 94.4 and negative PV 65.0 for prediction of IR in HCV patients (Table 8 , Figure 1 ).
At Cut-off value of serum Fetuin-A >4.9 mg/mL, sensitivity was 72.41, specificity was 79.31, positive PV was 77.8 and negative PV was 74.2 for prediction of DM in HCV patients ( Table 9 , Figure 2 ). 
Control N=28
Fetuin-A, mg/mL (Mean ± SD)
3.8 ± 0.9 5.5 ± 1.5 2.4 ± 0.7 1 ± 0. Fetuin-A is a circulating plasma glycoprotein, produced in hepatocytes and secreted into serum, it was found to be a natural inhibitor of the insulin receptor tyrosine kinase [30] . Thus, Fetuin-A is thought to be involved in the pathogenesis of insulin resistance [31,32].
Among the randomly selected 115 subjects included in this study the Mean ± SD of age was 46.3 ± 3.7 years, 50.4% females, 49.6 % males and the Mean ± SD of BMI was 23.3 ± 2 kg/m 2 .
In this study, there was statistically significant difference of ALT, AST levels among studied groups which were higher in HCV & DM followed by HCV when compared to DM and control groups. As the liver injury due to HCV and steatosis that is associated with IR is associated with increased level of ALT and AST in serum [33] . Also, Kim et al. [34] concluded that there was significant association between serum levels of liver enzymes and risk of type 2 diabetes.
There was statistically significant difference of glucose homeostasis parameters among studied groups, where HOMA-IR, fasting blood glucose, fasting serum insulin and 2-hour post prandial blood glucose level were higher among HCV & DM than DM with statistically significant difference, as insulin resistance and T2DM represent unique extrahepatic metabolic complications for chronic hepatitis C virus infection [35] .
Also, insulin and HOMA-IR levels were increased in DM than HCV and control subjects that were in agreement with Ahmed et al. [36] .
There was statistically significant difference as regard lipid profile among different groups, where LDL, TG, TC levels were elevated significantly and HDL level was decreased in HCV&DM followed by DM when compared to HCV and control groups. Kralj Regarding the diagnostic validity of serum Fetuin-A as a predictor for IR in HCV patients at Cut-off value >5.2 mg/mL, AUC was 0.741, the sensitivity was 54.84 % and specificity was 96.30%.This indicates that serum Fetuin-A has important and specific role for IR induced by HCV infection. Also, regarding the diagnostic validity of serum Fetuin-A as a predictor for DM in HCV patients at Cut-off value >4.9 mg/mL, AUC was 0.81, the sensitivity was 72.41% and specificity was 79.31%.
Finally, it can be concluded that serum level of Fetuin-A was higher in HCV patients than non HCV subjects and among diabetic patients than non diabetic subjects. Also, serum levels of Fetuin-A were markedly elevated among HCV & DM patients followed by HCV patient groups when compared to DM and control groups. Serum Fetuin-A levels was positively correlated with glucose homeostasis parameters in both HCV and HCV&DM patients. Fetuin-A, may be target for therapeutic modalities for the treatment of insulin resistance in HCV patients. Future studies on large scale to standardize cut off value of Fetuin-A as a predictor for IR and DM in HCV patients may be needed.
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